Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Tivozanib and Erlotinib as Initial Treatment for Metastatic NSCLC
NCT01728181Phase 2Withdrawn
- Sponsor
- University of Utah
- Start
- Nov 2013
- Primary completion
- Mar 2016
- Modality
- Fragment-Derived Small Molecules, Allosteric Modulators, Orthosteric Ligands
01
Overview
A Phase 2 trial of tivozanib in non-small cell lung cancer (NSCLC), sponsored by University of Utah. Planned start Nov 2013; status: withdrawn.
02
Drugs
tivozanib
03
Conditions
non-small cell lung cancer (NSCLC)
Beyond the preview
Go deeper on NCT01728181.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT01728181.